However, CTXpre/CD4post-experienced Il18r1 KO mice showed similar therapeutic efficacy as C57BL/6 wild-type mice, implying that the anti-melanoma effect of highly tumor-specific IL-18Rαhi ex-T cells outweigh that of IL-18Rαhi en-T cells. The gene discussed is IL18R1; the disease is melanoma.